HIGHLIGHTS
- who: GalNAc-conjugated et al. from the Department of Chemistry, Faculty of Natural Science, Mangosuthu University of Technology, Umlazi, South Africa have published the research work: Development of Novel siRNA Therapeutics: A Review with Focus on Inclisiran for the Treatment of Hypercholesterolemia, in the Journal: (JOURNAL)
- what: The results of this study demonstrated clinical evidence for the use of PCSK9 as a therapeutic target for a significant reduction in LDL cholesterol, which can be effective for at least six months after starting treatment. The Phase 3 trial focused on evaluating the use of inclisiran in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.